Phase I, single-center, double-blind, randomized, placebo-controlled, parallel-group study of
the safety, tolerability, and pharmacokinetics (PK) in plasma and urine, of multiple
ascending doses of ALZ-801 (capsule, Part 1; prototype tablet Part 2) and the primary
metabolite in healthy male or female subjects.